Jeevan Scientific Technology Ltd

Fund-raising and deviation status

• Mode of fund raising: Preferential Allotment (Equity).
• Date of raising funds: 02.01.2026; Amount raised: 3074 Lakhs.
• Report filed for quarter ended: 30 June 2026.
• Deviation/variation in use of funds raised: No.
• Monitoring agency: Not applicable.
• Original objects: No deviation; allocations unchanged.
• Utilisation status: Not disclosed due to no deviation.

Management changes – appointments & retire-by-rotation

• Re-appoint Snigdha Mothukuri as Whole Time Director for 3 years from 02.11.2026; related to Kuchipudi and Kishore.
• Continue Mr. Nageswar Rao Yarllagadda as Whole Time Director beyond age 70; subject to member approval.
• Re-appoint Mr. Nageswar Rao Yarllagadda as Whole Time Director for 3 years from 23.06.2027; shareholders' approval.
• Re-appoint Mr. Suryaprakasa Rao Bommisetti as Independent Director for 5 years from 25.03.2027; shareholders' approval.
• Appoint Kolli Srinivas Rao as additional Independent Director for 5 years from 13.08.2026; shareholders' approval.
• Re-appoint Snigdha Mothukuri as Director, retire by rotation.
• Re-appoint Krishna Kishore Kuchipudi as Director, retire by rotation.

Director profiles

• Snigdha Mothukuri: Hons; master's from Columbia and IIT Madras; prior roles in global firms.
• Nageswar Rao Yarllagadda: 33+ years' leadership; Director at Sri Surya Wheels Pvt Ltd.
• Suryaprakasa Rao Bommisetti: Chartered Accountant; partner at Pundarikashyam & Associates; 30+ years in audit/finance.
• Kolli Srinivas Rao: Chartered Accountant; partner at K Rao & Associates; SEBI/NISM certified.
• Krishna Kishore Kuchipudi: Promoter and MD; BTech; led Jeevan Mita Chit Fund.

Related-party disclosures

• Snigdha Mothukuri is related to Kuchipudi and Kishore.
• No other Directors or KMP are related to each other.
• Kolli Srinivas Rao: no disclosed related-party ties.

Meeting Details

• No meeting date, time, or location disclosed in this chunk.

Key Agenda Items

• No agenda items disclosed in this chunk.

Other Notes

• No other material information available in this chunk.

Dematerialisation status

• Dematerialised securities for quarter ended 30 June 2026 furnished to exchanges.
• RTA confirmed no dematerialisation requests were received during the quarter.

Standalone FY26 results

• 📊 Revenue from operations rose 23.7% YoY to ₹5,393.13 lakh.
• 📊 Total income increased 24.6% YoY to ₹5,511.91 lakh.
• 📊 PBT rose to ₹263.94 lakh from ₹77.05 lakh.
• 📊 PAT increased to ₹165.01 lakh from ₹73.67 lakh.
• 📊 FY26 EPS was ₹0.83 basic and ₹0.98 diluted.
• 📊 Q4FY26 revenue was ₹1,837.73 lakh, up 105.9% YoY.
• 📊 Q4FY26 PAT was ₹159.48 lakh versus loss of ₹133.71 lakh.
• 📊 Other expenses rose to ₹2,302.09 lakh from ₹1,783.97 lakh.
• 📊 Employee costs increased to ₹1,799.40 lakh from ₹1,565.30 lakh.
• 📊 Finance costs rose to ₹137.77 lakh from ₹103.56 lakh.

Consolidated FY26 results

• 📊 Revenue from operations rose 31.4% YoY to ₹6,153.71 lakh.
• 📊 Total income increased 31.6% YoY to ₹6,250.98 lakh.
• 📊 Consolidated PBT was ₹209.20 lakh versus ₹5.07 lakh last year.
• 📊 Consolidated PAT rose to ₹103.33 lakh from ₹5.90 lakh.
• 📊 Consolidated FY26 EPS was ₹0.52 basic and ₹0.61 diluted.
• 📊 Q4FY26 consolidated revenue was ₹2,128.70 lakh, up 111.8% YoY.
• 📊 Q4FY26 consolidated PAT was ₹184.18 lakh versus loss of ₹126.22 lakh.
• 📊 Other expenses increased to ₹2,519.98 lakh from ₹1,857.34 lakh.
• 📊 Employee costs increased to ₹2,164.38 lakh from ₹1,705.71 lakh.
• 📊 Finance costs rose to ₹203.94 lakh from ₹176.09 lakh.

Balance sheet and cash flow

• 📊 Standalone cash and cash equivalents rose to ₹946.79 lakh from ₹20.59 lakh.
• 📊 Consolidated cash and cash equivalents rose to ₹950.55 lakh from ₹24.23 lakh.
• 📊 Standalone total assets increased to ₹9,925.27 lakh from ₹7,061.51 lakh.
• 📊 Consolidated total assets increased to ₹10,656.72 lakh from ₹7,825.05 lakh.
• 📊 Standalone trade receivables rose to ₹1,853.38 lakh from ₹1,439.09 lakh.
• 📊 Consolidated trade receivables rose to ₹2,068.31 lakh from ₹1,594.22 lakh.
• 📊 Standalone borrowings were ₹1,158.03 lakh, including ₹522.93 lakh current borrowings.
• 📊 Consolidated borrowings were ₹1,715.90 lakh, including ₹705.98 lakh current borrowings.
• 📊 Standalone operating cash flow was ₹255.50 lakh.
• 📊 Consolidated operating cash flow was ₹41.64 lakh.
• 🧱 Standalone capex was ₹1,135.39 lakh, including capital advances and creditors.
• 🧱 Consolidated capex was ₹818.08 lakh.

Capital actions and audit

• 📍 The company allotted 40.85 lakh equity shares and 35 lakh convertible warrants during FY26.
• 📊 Standalone equity share capital increased to ₹1,991.90 lakh from ₹1,583.40 lakh.
• 📊 Consolidated equity share capital increased to ₹1,991.90 lakh from ₹1,583.40 lakh.
• 📍 Statutory auditors issued an unmodified opinion on standalone and consolidated results.

Business and segment

• 🗒️ The company operates in Clinical Research Services.
• 🗒️ Consolidated results include subsidiary Nayas Laboratories Private Limited and associate Naya Pharma Private Limited.

Financial results

• Approved audited standalone and consolidated results for quarter and year ended 31 March 2026.
• Statutory auditors issued unmodified opinions on both standalone and consolidated results.

Board decisions

• Approved grant of 4,80,000 stock options under JSTL ESOP Scheme 2016.
• Approved allotment of 1,61,250 equity shares on ESOP exercise.
• Allotted shares increased paid-up equity capital to Rs. 20,08,02,150.

Appointments

• Appointed M/s. KP & Associates as internal auditors for FY 2026-27, effective 29 May 2026.

ESOP details

• Options vest 25% annually over four years from grant date.
• Exercise period is one to five years from last vesting date.

Consolidated group update

• Consolidated results included subsidiary Nayas Laboratories Private Limited and associate Naya Pharma Private Limited.
• Company made capital contribution in associate Naya Pharma Private Limited during the quarter.